Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | VP, Research | February 03, 2005 | February 07, 2005 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VERTEX PHARMACEUTICALS INC / MA
Report date February 03, 2005 · Filed February 07, 2005
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 55,516 |
Reported balance
After 2005-02-03 transaction · row 1
1 source rowRow 1 · 2005-02-03 · Grant · Acquired 2,375 · Balance 55,516 F1: Stock grant made under 1996 Stock and Option Plan, vesting 02/03/2009, subject to acceleration upon achievement of certain performance-based milestones. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $10.41 · Expires 2015-02-02 | Direct | 266,682 |
Reported balance
After 2005-02-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2005-02-03 · Grant · Acquired 10,313 · Balance 266,682 F2: Right to buy under 1996 Stock and Option Plan, vesting in 16 equal quarterly installments from 02/03/2005. |
| Common StockSEC Table I · non-derivative | Indirectshares 401(k) | 1,316 |
Reported balance
Holding disclosure · report date 2005-02-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,316 |
Filing footnotes · ownership attribution and instrument terms
F1: Stock grant made under 1996 Stock and Option Plan, vesting 02/03/2009, subject to acceleration upon achievement of certain performance-based milestones.
F2: Right to buy under 1996 Stock and Option Plan, vesting in 16 equal quarterly installments from 02/03/2005.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 03, 2005 Filed Feb 7, 2005 21:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 10,313 | $0.00 Strike: $10.41 | $0.00 |
DisclosureSEC source: 0000875320-05-000013 · edgar.xml · derivative · entry 3 Negulescu Paul A · CIK 0001289808 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,682 Underlying: Common Stock · 10,313 shares Expires 2015-02-02 F2 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting in 16 equal quarterly installments from 02/03/2005. Read SEC document |
| February 03, 2005 Filed Feb 7, 2005 21:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 2,375 | $0.01 | $23.75 |
DisclosureSEC source: 0000875320-05-000013 · edgar.xml · nonDerivative · entry 1 Negulescu Paul A · CIK 0001289808 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,516 F1 · shares: Stock grant made under 1996 Stock and Option Plan, vesting 02/03/2009, subject to acceleration upon achievement of certain performance-based milestones. Read SEC document |
| October 07, 2004 Filed Oct 12, 2004 18:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 7,500 | $0.00 Strike: $11.27 | $0.00 |
DisclosureSEC source: 0000875320-04-000112 · edgar.xml · derivative · entry 1 Negulescu Paul A · CIK 0001289808 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,369 Underlying: Common Stock · 7,500 shares Expires 2014-10-06 F1 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting quarterly over 4 years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.